Blockchain Registration Transaction Record

Melanoma Test Shows 3-Fold Risk Stratification in Landmark Study

SkylineDx's Merlin CP-GEP test shows 3-fold melanoma risk stratification in JAMA Surgery study. Largest genomic trial helps guide sentinel node biopsy decisions for personalized care.

This breakthrough in melanoma diagnostics represents a significant advancement in personalized cancer care that directly impacts patient outcomes and treatment decisions. For the thousands of people diagnosed with melanoma each year, the Merlin CP-GEP test provides unprecedented accuracy in determining who truly needs invasive sentinel lymph node biopsy procedures versus who can safely avoid them. This matters because sentinel node biopsies carry risks including infection, lymphedema, and nerve damage, while also adding substantial healthcare costs. By accurately identifying low-risk patients who can forego this procedure, the test reduces unnecessary surgeries, minimizes complications, and decreases healthcare expenses. For high-risk patients, it ensures they receive the necessary interventions promptly. In an era where precision medicine is transforming oncology, this test exemplifies how genomic technology can optimize treatment pathways, improve quality of life, and make cancer care more efficient and patient-centered.